ORIC Pharmaceuticals is a clinical stage biopharmaceutical company focused on enhancing the lives of patients by addressing therapeutic resistance in cancer. The company is developing innovative product candidates, including ORIC-114, a targeted inhibitor for specific cancer mutations, and ORIC-944, an allosteric inhibitor for prostate cancer. ORIC is committed to creating precision medicines that tackle various cancer resistance mechanisms and operates from its offices in South San Francisco and San Diego, California.